Loading organizations...
Key people at Global BioAccess Fund.
Global BioAccess Fund is an investment firm financing companies developing novel therapeutics and devices. It targets serious unmet medical needs across Oncology, I&I, cardiovascular, CNS, and rare diseases. The fund provides capital to early-stage ventures, supporting investigational new drug (IND) submissions and clinical trials to advance scientific discoveries towards patient care.
Established in 2021, the fund is led by Managing Partners Bruce Roberts and Ted Moon. Its formation leverages the extensive experience of its core team, which brings over 25 years of collective history in life sciences investment through the principal investment business of RMG. This deep domain expertise underpins the firm’s strategy to nurture transformative biotechnology companies.
The fund supports early-stage biotechnology companies needing capital for preclinical development and initial clinical trial phases. Global BioAccess Fund’s vision is to accelerate novel science, facilitating the creation of new medicines. It partners with innovative entrepreneurs to deliver impactful solutions for patients.
Key people at Global BioAccess Fund.
Global BioAccess Fund has 3 tracked investments across 3 companies. The latest tracked deal is $67.0M Series B in Cartography Biosciences in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2025 | Cartography Biosciences | $67.0M Series B | — | BackBone Ventures, Pfizer Venture Investments, Samsara BioCapital, Daniel Vasella, Reinhard Ambros, 8VC, AME Cloud Ventures, Amgen Ventures, Andreessen Horowitz, Catalio Capital, Finchley Healthcare Ventures, Gaingels, LG Corp, Lotte Holdings, Wing Venture Capital |
| Dec 1, 2023 | Odyssey Therapeutics | $100.0M Series C | Lorence KIM | OrbiMed, SR ONE, Third Rock Ventures, AB Magnitude Ventures Group, Alexandria Venture Investments, Blackmars Capital, Catalio Capital, Colt Ventures, Creacion Ventures, CU Healthcare Innovation Fund, Fidelity Management & Research Company, Foresite Capital, General Catalyst, HBM Healthcare Investments, KB Investment, Racing Beach Ventures, T. Rowe Price Associates, Walleye Capital, Woodline Partners |
| Sep 1, 2023 | Acesion Pharma | $48.0M Series B | TIM Shannon, NIK Economopoulos | Canaan Partners, Hatteras Venture Partners, OrbiMed, Jørgen Søberg Petersen |
